Insulet Corporation (NASDAQ:PODD) Shares Acquired by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC increased its position in Insulet Corporation by 33.9% during the first quarter, holding a total of approximately $15.6 million in shares.
• Multiple institutional investors have recently made significant moves with Insulet, with Allspring Global Investments raising its stake by 55.5% and Farther Finance Advisors increasing theirs by 85.1% in the same quarter.
• Insulet reported a Q1 EPS of $1.02, surpassing the consensus estimate of $0.81, and achieved a revenue of $569 million, reflecting a 28.8% year-over-year increase.

Natixis Advisors LLC raised its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 33.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,412 shares of the medical instruments supplier's stock after buying an additional 15,041 shares during the period. Natixis Advisors LLC owned about 0.08% of Insulet worth $15,602,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PODD. Baader Bank Aktiengesellschaft boosted its holdings in shares of Insulet by 12.4% during the first quarter. Baader Bank Aktiengesellschaft now owns 1,009 shares of the medical instruments supplier's stock worth $259,000 after purchasing an additional 111 shares during the period. Bayforest Capital Ltd boosted its holdings in shares of Insulet by 106.8% during the first quarter. Bayforest Capital Ltd now owns 608 shares of the medical instruments supplier's stock worth $160,000 after purchasing an additional 314 shares during the period. Thornburg Investment Management Inc. purchased a new stake in shares of Insulet during the first quarter worth about $4,325,000. Banque Cantonale Vaudoise purchased a new stake in shares of Insulet during the first quarter worth about $1,575,000. Finally, Federated Hermes Inc. boosted its holdings in shares of Insulet by 23.4% during the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock worth $166,198,000 after purchasing an additional 120,197 shares during the period.

Insider Transactions at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president directly owned 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.39% of the stock is currently owned by company insiders.

Insulet Trading Down 2.4%

NASDAQ:PODD traded down $6.77 during mid-day trading on Tuesday, hitting $281.00. 833,109 shares of the stock traded hands, compared to its average volume of 519,801. The stock has a market capitalization of $19.78 billion, a price-to-earnings ratio of 50.54, a PEG ratio of 2.57 and a beta of 1.35. Insulet Corporation has a 52 week low of $173.00 and a 52 week high of $329.33. The firm's 50 day moving average is $301.71 and its two-hundred day moving average is $282.64. The company has a quick ratio of 3.63, a current ratio of 4.47 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm's revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 EPS. On average, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PODD shares. Raymond James Financial reissued an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Oppenheimer raised their price target on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research report on Monday, April 28th. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research report on Tuesday, May 13th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $321.00.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.